References
- Horning S. J. Treatment approaches to the low-grade lymphomas. Blood 1994; 83: 881–884
- Gribben J. G., Nadler L. M. Purging of autologous bone marrow in the treatment of non-Hodgkin's lymphoma. Important Adv Oncol 1993; 139–156
- McLaughlin P., Hagemeister F. B., Swan F., Cabanillas F., Romaguera J., Rodriguez M. A., Lee M. S., Pate O., Sarris A., Younes A. Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma: High remission rates and reversion to negative of peripheral blood bcl-2 rearrangement. Ann Oncol 1994; 2: 73–77
- Keating M. J., O'Brien S., Plunkett W., Robertson L. E., Gandhi V., Estey E., Dimopoulos M., Cabanillas F., Kemena A., Kantarjian H. Fludarabine phosphate: a new active agent in hematologic malignancies. Semin Hematol 1994; 31: 28–39
- Rowinsky E. K., Donehower R. C. Paclitaxel (taxol) [published erratum appears in N Engl J Med 1995 Jul 6; 333(1):75]. N Engl J Med 1995; 332: 1004–1014
- Rowinsky E. K., Onetto N., Canetta R. M., Arbuck S. G. Taxol: the first of the taxanes, an important new class of antitumor agents. Semin Oncoi 1992; 19: 646–662
- Younes A., Sarris A., Melnyk A., Romaguera J., McLaughlin P., Swan F., Rodriguez M. A., Hagemeister F., Moore D., North L., Cabanillas F. Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 583–587
- Redman J. R., Cabanillas F., Velasquez W. S., McLaughlin P., Hagemeister F. B., Swan F., Jr, Rodriguez M. A., Plunkett W. K., Keating M. J. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J Clin Oncol 1992; 10: 790–4
- Wilson W. H., Chabner B. A., Bryant G., Bates S., Fojo A., Regis J., Jaffe E., Steinberg S. M., Goldspiel B. R., Cheson B., Wittes R. E. Phase II study of paclitaxel in relapsed Non-Hodgkin's lymphomas. J Clin Oncol 1995; 13: 381–386
- Younes A., Ayoub J., Hagemeister F., McLaughlin P., Sarris A., Rodriguez M. A., Swan F., Romaguera J., Martin J., Cabanillas F. No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion schedule. J. Clin. Oncol 1996; 14: 543–548
- Horning S. J. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993; 20: 75–88
- Grossbard M. L., Press O. W., Appelbaum F. R., Bernstein I. D., Nadler L. M. Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 1992; 80: 863–878